The breast implant surface technology history of the 2010s is not a simple progression from “old” textured devices to “new” smooth ones. Implant surfaces were developed to solve specific engineering and biological problems: excessive movement, rotation of shaped implants and the firm, contracting capsule that can form around a breast implant. By the 2010s, manufacturers were offering several surface designs, including smooth, microtextured and more aggressively textured shells. Each was built around a different balance of tissue interaction, stability, handling and risk.
The decade also exposed the limits of judging an implant by its surface name alone. A useful breast implant surface technology history must make clear that “textured” does not describe one uniform technology. Roughness, pore size, manufacturing method, surface area, shell construction, filler, implant shape and clinical indication can differ substantially between devices. A microtextured shell is not automatically interchangeable with a macrotextured shell, and neither label by itself proves a lower contracture rate or a particular aesthetic result.
This article explains why surface technology developed, what manufacturers and surgeons hoped it would achieve, what the evidence could and could not show in the 2010s, and why the current regulator and manufacturer information for the exact device remains essential. The historical discussion includes cosmetic augmentation and reconstruction evidence where relevant, but those populations are not interchangeable. This is an evidence review, not a recommendation for a brand, surface or individual operation.
What is the surface of a breast implant?
Every breast implant has an outer shell, and the shell can be smooth or intentionally modified. The filler inside may be silicone gel or saline; filler and surface are separate characteristics. A silicone gel implant can have a smooth or textured shell, as can a saline-filled device where that combination is approved and available. Shape, projection, width and pocket placement are also separate decisions.
In everyday clinical language, a smooth implant has a shell without deliberately created macroscopic irregularities. It is designed to have relatively low friction against the surrounding capsule and may move within the pocket as the breast moves. That mobility can be part of the intended behaviour, but it can also mean that pocket dimensions, soft-tissue coverage and support have to be planned carefully.
A textured implant has a deliberately altered shell surface. The texture may be created by a salt-loss process, an imprint or another proprietary manufacturing method. The purpose is to change how the implant contacts the surrounding tissue rather than merely to make the shell look different under a microscope. The amount and pattern of roughness matter: two products described simply as “textured” may create different mechanical and biological interfaces.
The words microtextured and macrotextured are useful but not perfectly consistent in older product literature. The historical review by Deva and colleagues describes the ISO 14607:2018 roughness categories as smooth below 10 micrometres, microtextured from 10 to 50 micrometres and macrotextured above 50 micrometres of average roughness. These ranges are a classification aid, not a complete description of a living tissue interface. Pore geometry, distribution, depth, manufacturing residue and the rest of the device may also matter.
Some manufacturers and publications have used terms such as “microtexture,” “fine texture,” “nanotexture” or brand-specific names in ways that do not map neatly onto one another. A patient should therefore ask for the exact model and the manufacturer’s current patient information instead of assuming that a label used in a brochure has one universal technical meaning.
Why were textured surfaces developed?
The original motivation was not cosmetic marketing. Early smooth-shelled implants could be associated with a tight, firm fibrous capsule known as capsular contracture. A capsule forms around any implanted device as part of the body’s foreign-body response, but it can become unusually thick, contracted or painful. It may make the breast feel hard, distort the implant or lead to revision surgery.
Surface modification was one attempt to influence that response. The history of implant design describes polyurethane foam-coated implants in the 1970s. Tissue could grow into the foam-like surface, and clinical experience suggested lower rates of clinically significant contracture in some groups. The idea was then adapted into textured silicone shells, seeking some of the tissue interaction without retaining a polyurethane foam coating itself.
There was a second objective: stability. A smooth implant has relatively little friction with the pocket. A textured shell was intended to increase friction or tissue adherence, reducing micro-shifting and, in selected cases, helping the implant remain in a planned orientation. This became particularly relevant as anatomically shaped and form-stable implants became more common. A shaped implant has a designed top and bottom; rotation can therefore change the contour in a way that is less relevant to a symmetrical round implant.
These aims were rational, but rational design intent is not the same as proof of universal clinical benefit. The result depends on the exact surface, implant shape, pocket, tissue quality, operation, follow-up period and patient population. A surface cannot compensate for an implant that is too wide, too large, poorly supported or inappropriate for the available soft tissue.
What did the 2010s surface options try to achieve?
Smooth shells: mobility with less intentional tissue adherence
Smooth shells were attractive because they permitted movement and did not deliberately encourage tissue ingrowth into the outer shell. This could make the implant easier to reposition or exchange during later surgery and avoided some of the mechanical consequences of strong adherence. Smooth implants were used with both round and shaped designs, although shaped implants created a stronger reason to discuss rotation and stability.
Smooth does not mean complication-free. A smooth implant can move, become displaced, develop rippling or be affected by capsular contracture, trauma, gravity, changes in skin quality or the size of the pocket. It also remains an implanted medical device with possible rupture, pain, infection, asymmetry and the potential need for further surgery. “Smooth” is a surface description, not a lifetime safety claim.
More aggressively textured shells: fixation and capsule disruption
Coarser or macrotextured shells were intended to create a stronger tissue interface. The proposed benefits included better fixation, less rotation of anatomic implants and disruption of the regular circumferential alignment of collagen fibres in the capsule. The theory was that a less organised capsule might contract less strongly around the implant.
The evidence behind these claims was uneven. Some studies reported lower contracture rates with textured devices, but older comparisons often used different implant generations, different pocket planes and different surgical protocols. Many relied on the Baker grading system, which includes subjective assessments of appearance and firmness. Some studies involved reconstruction patients, revision patients or selected cohorts rather than a representative population undergoing primary cosmetic augmentation.
The 2010s therefore contained a mismatch between confident surface claims and the difficulty of isolating surface as the causal factor. A lower contracture rate in one series might reflect the surface, but it might also reflect submuscular placement, antibiotic or antiseptic practice, pocket control, patient selection, follow-up or how contracture was defined. The same surface could perform differently in a thinly covered reconstructive breast and a primary augmentation patient with more native tissue.
Microtextured and fine-textured shells: the proposed middle path
Microtextured devices were developed or promoted as a less aggressive form of texturing. The intended compromise was to retain some increase in friction and control of movement while limiting the degree of tissue disruption, debris or biological stimulation associated with coarser surfaces. In theory, a finer surface might provide enough interaction for stability without behaving like a heavily adherent macrotexture.
That compromise should be described as a design objective, not a settled clinical conclusion. “Microtextured” is not a guarantee of reduced capsular contracture, reduced malposition or zero BIA-ALCL risk. Clinical outcomes require device-specific data with a defined comparator, follow-up duration and patient population. A study of a particular microtextured implant cannot automatically be used to describe every fine-textured or so-called nanotextured product.
Surface roughness also has a mechanical trade-off. More tissue adherence can help hold an implant in place, yet it can make later removal or pocket change more demanding. If the breast changes with pregnancy, weight fluctuation, ageing or a later lift, an implant that is strongly integrated into the surrounding tissues may not behave like a freely mobile smooth device. The right balance depends on the patient’s anatomy and the reason for choosing the device.
Why surface comparisons became more complicated
The 2010s brought better awareness that “texture” is not a binary variable. A surface can differ in average roughness, pore diameter, pore depth, pattern, total surface area and manufacturing process. The outer shell may also have a smooth posterior patch rather than one identical texture over every part of the implant. These details affect contact with the capsule and the amount of tissue integration.
An implant’s surface also interacts with its filler and shape. A form-stable, anatomically shaped implant may need positional control for a different reason from a round, mobile implant. A cohesive gel may alter the way the device holds its contour, while a saline device may have different deflation and fold behaviour. The patient’s soft-tissue thickness influences visibility and palpability. The pocket and the surgical technique influence how much freedom the implant has to move.
This makes decade-based comparisons unreliable. An implant sold in 2012, 2015 or 2019 may not share the shell, gel, surface or regulatory status of another device sold in the same year. A company may change a product through an approved supplement, discontinue a model, change its trade name or update its patient labelling after post-market information becomes available. Product records are more informative than a generic statement such as “I have a textured implant.”
The safety turning point: BIA-ALCL and the 2019 BIOCELL recall
The most important change in surface discussions during the decade was the recognition of breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. BIA-ALCL is a rare type of non-Hodgkin lymphoma that usually develops in the fluid or fibrous capsule around an implant; it is not breast cancer. The FDA first identified a possible association in 2011 and continued reviewing medical-device reports, scientific literature, registries and post-approval information.
By 2019, the FDA stated that the risk of BIA-ALCL was higher with textured implants than with smooth implants. The agency requested that Allergan recall its BIOCELL textured breast implants and tissue expanders from the U.S. market. The recall notice records that both silicone-filled and saline-filled BIOCELL devices were included, while Allergan’s smooth and MICROCELL products were not affected by that specific recall. This distinction is important: the action concerned identified products and a specific surface technology; it was not a finding that every implant with any form of surface modification had the same risk.
The recall changed the balance of the surface conversation. Before the signal became prominent, texture was often discussed mainly as a solution to contracture or rotation. After the signal, the potential biological consequences of the tissue interface became central. A surface that encourages more interaction may offer an intended mechanical benefit, but it can also create a different environment around the device. The exact mechanism and the size of risk can vary by surface and product, and surveillance continues to refine what is known.
Patients should not interpret this history as a reason for panic or as a reason to ignore a new symptom. The FDA’s BIA-ALCL information says that persistent swelling, a mass or pain near an implant can occur years after placement and needs medical assessment. For an asymptomatic patient, the FDA does not recommend routine removal of textured implants solely because of concern about BIA-ALCL. A personal decision about removal may still be discussed, but removal is surgery with its own risks and should follow examination, device identification and informed discussion.
Why current regulator information matters more than a 2010s label
The 2010s history explains why surfaces were made, but it cannot tell a patient what to do with a particular implant in 2026. Current regulator information can change as post-market evidence, recalls, safety communications, approved products and patient labelling evolve. The FDA’s current breast implant pages state that implant characteristics include shell thickness, surface texture, size and shape, and they link to product-specific labelling and post-approval studies.
The FDA’s labeling page distinguishes original labeling from current labeling updated with post-approval information. It also lists approved products and their current patient documents. This is a practical reason to keep the manufacturer, model, style, size, serial or lot information and device card. The exact surface is part of that record, but it should be read together with filler, shape, approval status and the patient’s clinical history.
Current U.S. information should not be mistaken for a worldwide list of what is legal or available. A device may have different approval, registration, recall or distribution status in Turkey, the European Union, the United Kingdom, Australia, Canada or another country. Regulatory status is also not the same as a personal recommendation. Before surgery, the patient should receive the manufacturer’s current patient booklet and understand the risks and benefits of the specific device proposed.
The FDA’s labeling recommendations call for prominent risk communication, a boxed warning, a patient decision checklist and a device card. They also emphasise that the information should be updated as new data are collected. This is exactly why a historical article should link readers to current regulator pages instead of treating the 2010s as the final word.
What should a patient ask about a surface today?
Before breast augmentation or revision, useful questions include:
- What is the exact manufacturer, model, filler, shape and surface of the proposed implant?
- Is the surface described as smooth, microtextured, macrotextured, polyurethane-coated or by a manufacturer-specific name?
- What evidence supports this device’s proposed benefit for movement, rotation or capsular contracture in patients like me?
- What are the surface-specific risks, including the current regulator information about BIA-ALCL?
- Will I receive the current patient booklet, decision checklist and device card, and where will I find updates?
- How would the surface affect a future implant exchange, pocket change, lift or removal if my breast changes later?
The surgeon should be able to explain the surface as one part of a broader plan that includes breast-base width, soft-tissue coverage, implant dimensions, pocket and patient goals. A surface chosen to solve one problem may create a different trade-off. The most trustworthy explanation names both the intended benefit and the uncertainty around it.
For procedural context, the site’s breast augmentation operation page discusses anatomy and surgical planning. The practical guide to smooth versus textured breast implants provides a shorter patient-focused comparison. Readers who want to understand the filler rather than the shell can review silicone versus saline breast implants. The history of cohesive gel and anatomical implants explains why surface, shape and gel development became interdependent design questions.
If a patient is reviewing a current treatment pathway, the breast augmentation all-inclusive package page can provide service context. It should not replace product-specific labeling or the surgeon’s risk discussion.
Limitations of the evidence
Surface studies from the 2010s are difficult to combine because devices, texture categories, patient populations, surgical planes, follow-up periods and outcome definitions differ. “Textured” may include fine, micro- or macrotextured products, while some papers use manufacturer-specific terminology without reporting all surface measurements. A classification based on average roughness does not capture every feature that may influence tissue interaction.
Many clinical studies were retrospective, non-randomised or supported by manufacturer data. Capsular contracture was often graded clinically, and grading can vary between observers. A study designed to assess contracture may not have enough follow-up to assess a very rare lymphoma. Conversely, a registry or adverse-event report can identify a safety signal but cannot always establish incidence or causation because the denominator—the number of people exposed to each exact device—may be uncertain.
Historical evidence also mixes cosmetic augmentation and reconstruction. Reconstruction may involve mastectomy, radiotherapy, thin tissue coverage or a staged expander-to-implant pathway. Those factors can alter the risk of contracture, malposition, infection and revision. A result in reconstruction should not be advertised as a prediction for primary cosmetic augmentation.
Finally, a current regulator page can change after publication. This article records the evidence and regulatory information checked on 10 September 2026, but patients and clinicians should verify the latest product-specific labeling, recall notices and local regulatory status before a procedure or revision.
Conclusion
The 2010s were a decisive period in breast implant surface technology history because they revealed both the promise and the limits of engineered tissue interaction. Smooth shells offered less intentional adherence and potentially more movement. Textured shells were developed to improve fixation, reduce rotation and disturb the capsule’s contraction pattern. Microtextured and fine-textured devices were promoted as a possible middle path between mobility and adherence. None of those design intentions proves that one surface is best for every patient.
The decade also changed the safety question. Evidence linking BIA-ALCL more strongly with textured surfaces, followed by the 2019 BIOCELL recall, meant that surface could no longer be discussed only as a solution to capsular contracture or implant movement. The clinically responsible approach is device-specific: identify the exact shell and model, review current regulator and manufacturer information, discuss the intended benefits and trade-offs, and understand how future monitoring or surgery may be affected.
The wider research sequence follows these questions separately. The planned review of the 2019 BIOCELL recall and breast implant safety surveillance examines the regulatory response in detail; the article on capsular contracture biology and risk factors explores the tissue response that originally motivated surface modification; and the planned BIA-ALCL surface evidence review addresses the rare safety signal without treating all textured products as identical.
This history is useful precisely because it resists a one-word answer. “Smooth,” “textured” and “microtextured” are starting points for a consent conversation, not substitutes for evidence, current labeling or individual assessment.